OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Price, News & Analysis

$1.14
-0.04 (-3.39%)
(As of 04/23/2024 ET)
Today's Range
$1.14
$1.18
50-Day Range
$1.05
$3.00
52-Week Range
$0.39
$18.00
Volume
316 shs
Average Volume
5,995 shs
Market Capitalization
$5.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ARTH stock logo

About Arch Therapeutics Stock (OTCMKTS:ARTH)

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Stock Price History

ARTH Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Arch Therapeutics Inc ARTH
Arch Therapeutics Provides Year End Operational Update
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Arch Therapeutics Provides AC5® Commercialization Update
Dr. Arth Patel
Double Arch
Arch Therapeutics Inc (ARTHD)
ARTH Arch Therapeutics, Inc.
See More Headlines
Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/24/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
OTCMKTS:ARTH
Previous Symbol
NASDAQ:ARTH
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-6,980,000.00
Net Margins
-6,809.45%
Pretax Margin
-6,808.58%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
($2.43) per share

Miscellaneous

Free Float
4,529,000
Market Cap
$5.40 million
Optionable
Not Optionable
Beta
3.53
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Terrence W. Norchi M.D. (Age 59)
    Co-Founder, Chairman, President & CEO
    Comp: $450.5k
  • Mr. Michael S. Abrams (Age 54)
    CFO & Treasurer
    Comp: $325k
  • Dr. Rutledge Ellis-Behnke Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Shawn Carlson
    Vice President of Sales

ARTH Stock Analysis - Frequently Asked Questions

How have ARTH shares performed in 2024?

Arch Therapeutics' stock was trading at $7.24 at the beginning of 2024. Since then, ARTH stock has decreased by 84.3% and is now trading at $1.14.
View the best growth stocks for 2024 here
.

When is Arch Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ARTH earnings forecast
.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Tuesday, February, 20th. The biotechnology company reported ($0.57) earnings per share for the quarter. The biotechnology company had revenue of $0.05 million for the quarter.

What other stocks do shareholders of Arch Therapeutics own?
How do I buy shares of Arch Therapeutics?

Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ARTH) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners